Form 4: Anterix Inc. Executive Gena L. Ashe Reports Stock Option Grant
SEC Filing
Gena L. Ashe, Chief Legal Officer & Corp Sec of Anterix Inc., reports the acquisition of stock options.
Summary
- On May 20, 2025, Gena L. Ashe, Chief Legal Officer & Corp Sec of Anterix Inc., acquired 53,491 stock options with an exercise price of $34.96.
- The options vest in three equal annual installments starting May 20, 2026, and expire on May 20, 2035.
- Following the transaction, Ashe directly owns 53,491 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding executive compensation, and does not contain information that would significantly impact investor sentiment positively or negatively.
Positives
- The grant of stock options aligns the executive's interests with those of the shareholders.
Industry Context
Stock option grants are a common form of executive compensation in publicly traded companies, used to incentivize performance and align management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant could potentially impact shareholders by diluting equity if the options are exercised in the future.
Key Dates
| Date | Description |
|---|---|
| 05/20/2025 | Date of transaction: Grant of stock options. |
| 05/20/2026 | First vesting date for the stock options (1/3 of the shares). |
| 05/20/2035 | Expiration date of the stock options. |
| 05/22/2025 | Date of signature on the Form 4 filing. |
Keywords
stock options, Form 4, insider trading, Anterix Inc., ATEX, Gena L. Ashe, executive compensation, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.